Recent progress in melasma pathogenesis
- PMID: 26230865
- DOI: 10.1111/pcmr.12404
Recent progress in melasma pathogenesis
Abstract
Melasma is a common skin pigmentation condition. Given therapeutic difficulty as one of the biggest concerns, understanding of the etiology and pathogenesis of melasma becomes essential. UV irradiation, female sex hormones, and inflammatory processes are addressed as triggering factors with genetic predisposition. The mechanism of UV-induced melanogenesis has been extensively investigated as a model system to study melasma pathogenesis. Hitherto, treatment modalities for melasma are similar to other hyperpigmentation disorders. However, individual triggering factors induce a separate pigmentation disease, whose pathogenic mechanisms and clinical phenotypes are different from the ones encountered in melasma. Fortunately, there have been ongoing updates on melasma pathogenesis with regard to major triggering factors. Presence of certain factors working independently of UV exposure and role of dermal factors and microRNAs are being identified as novel discoveries about melasma pathogenesis. In this review, the melasma pathogenesis is reviewed in association with updated and new findings.
Keywords: UV; UV exposure-independent factors; dermal factors; estrogen; melasma; microRNAs; pathogenesis.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
Melasma: How hormones can modulate skin pigmentation.J Cosmet Dermatol. 2019 Apr;18(2):458-463. doi: 10.1111/jocd.12877. Epub 2019 Feb 18. J Cosmet Dermatol. 2019. PMID: 30779300 Review.
-
The clinicoaetiological, hormonal and histopathological characteristics of melasma in men.Clin Exp Dermatol. 2018 Jan;43(1):36-41. doi: 10.1111/ced.13234. Epub 2017 Sep 22. Clin Exp Dermatol. 2018. PMID: 28940653
-
H19 RNA downregulation stimulated melanogenesis in melasma.Pigment Cell Melanoma Res. 2010 Feb;23(1):84-92. doi: 10.1111/j.1755-148X.2009.00659.x. Epub 2009 Dec 4. Pigment Cell Melanoma Res. 2010. PMID: 19968822
-
Melasma treatment: A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor.Med Hypotheses. 2017 Apr;101:1-5. doi: 10.1016/j.mehy.2017.01.020. Epub 2017 Feb 3. Med Hypotheses. 2017. PMID: 28351480
-
[Melasma and aspects of pigmentary disorders in Asians].Ann Dermatol Venereol. 2012 Nov;139 Suppl 3:S92-5. doi: 10.1016/S0151-9638(12)70117-5. Ann Dermatol Venereol. 2012. PMID: 23260524 Review. French.
Cited by
-
Global research trends on melasma: a bibliometric and visualized study from 2014 to 2023.Front Pharmacol. 2024 Jul 25;15:1421499. doi: 10.3389/fphar.2024.1421499. eCollection 2024. Front Pharmacol. 2024. PMID: 39119611 Free PMC article. Review.
-
Understanding Melasma-How Can Pharmacology and Cosmetology Procedures and Prevention Help to Achieve Optimal Treatment Results? A Narrative Review.Int J Environ Res Public Health. 2022 Sep 24;19(19):12084. doi: 10.3390/ijerph191912084. Int J Environ Res Public Health. 2022. PMID: 36231404 Free PMC article. Review.
-
microRNAs in the Regulation of Melanogenesis.Int J Mol Sci. 2021 Jun 5;22(11):6104. doi: 10.3390/ijms22116104. Int J Mol Sci. 2021. PMID: 34198907 Free PMC article. Review.
-
Gomisin N Inhibits Melanogenesis through Regulating the PI3K/Akt and MAPK/ERK Signaling Pathways in Melanocytes.Int J Mol Sci. 2017 Feb 22;18(2):471. doi: 10.3390/ijms18020471. Int J Mol Sci. 2017. PMID: 28241436 Free PMC article.
-
Fibroblast morphology, growth rate and gene expression in facial melasma.An Bras Dermatol. 2022 Sep-Oct;97(5):575-582. doi: 10.1016/j.abd.2021.09.012. Epub 2022 Jul 12. An Bras Dermatol. 2022. PMID: 35840442 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources